SHINE MEDICAL TECHNOLOGIES FILES THE CONSTRUCTION PERMIT APPLICATION WITH NUCLEAR REGULATORY COMMISSION

Published on:

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.

As required by Federal regulations, the Construction Permit application consists of general information about SHINE, an analysis of environmental impacts from the construction and operation of the facility, if any, and a preliminary safety analysis of the planned facility. Today’s filing includes the environmental analysis and general and financial information about SHINE; the remaining portions of the preliminary analysis will be filed in the next several months.

SHINE’s filing begins the NRC’s process of formal acceptance and review, which is expected to

take approximately eighteen months. “This filing is an important milestone as SHINE carries out its plans to construct and operate a facility to produce medical isotopes in Janesville,” said SHINE CEO and founder Greg Piefer. “It represents a lot of hard work by our tem and is a significant step forward for building and operating a facility that will address an important worldwide health care issue.

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Cardiovascular Business
AI-enabled plaque assessments help cardiologists ID high-risk CAD patients

AI-enabled coronary plaque assessments deliver significant value, according to late-breaking data presented at TCT. These AI platforms have gained considerable momentum in recent months, receiving expanded Medicare coverage in addition to a new Category I CPT code.

Design by Adaptive Theme
Trimed Popup
Trimed Popup